Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
Key Highlights
- ➤Bluejay completes SanyoSeiko manufacturing site ahead of October 23 contractual deadline
- ➤Bluejay formally notifies Toray it fulfilled substantial manufacturing-site establishment obligation
- ➤ALURIS U.S. relationship adds complementary manufacturing pathway and supply-chain redundancy
- ➤Symphony IL-6 Test remains uncleared and unapproved by the FDA
- ➤SYMON-II pivotal study planned to support a 510(k) FDA application
Expert Statements
Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics
“Achieving this manufacturing milestone is an important accomplishment for Bluejay and another tangible step in our progression toward regulatory and commercial readiness.”
Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics
“Our manufacturing strategy is designed to extend beyond a single facility or geography. With the establishment of our manufacturing capability at SanyoSeiko and our strategic U.S. manufacturing relationship with ALURIS, we are working to build complementary manufacturing pathways that can provide greater flexibility, redundancy and supply-chain resilience.”
ACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that it has completed the establishment of a manufacturing site for Symphony™ cartridges, achieving a critical contractual milestone as the Company advances toward regulatory submission and potential commercialization. The milestone was achieved ahead of the October 23, 2026 contractual deadline established under Bluejay's amended license agreement with Toray Industries, Inc. ("Toray"). Bluejay has formally notified Toray that the Company has fulfilled its obligation to substantially complete establishment of a manufacturing site. Bluejay's manufacturing strategy is being developed around complementary manufacturing capabilities at SanyoSeiko Co., Ltd. in Japan and ALURIS Sciences, (previously Argonaut Manufacturing Services) in the United States. SanyoSeiko serves as the manufacturing site established under Bluejay's agreement with Toray and is an important component of the Company's Symphony cartridge manufacturing infrastructure.
Get started
Create a free account to read the full story.